NEW YORK/PRNewswire/ -- 

Report Scope
This report organizes information from diverse sources into a comprehensive report that includes an overview, market dynamics, disease type, leading blockbuster drug profiles, regulations, reimbursement and patents.It analyzes prevailing blood cancer treatment guidelines in different geographic regions.

Read the full report: https://www.reportlinker.com/p05691568 

The scope of the blood cancer therapeutic market is restricted to three disease areas: leukemia, lymphoma and multiple myeloma.Leukemia is classified into four sub-segments: chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

This report includes an overview of the global market scenario for blood cancer treatments with base year data from 2017, estimations for 2018 and forecasts for 2019 to 2023, using CAGR projections.Market data in value terms is provided at global, regional and country levels for disease areas.

This report forecasts the global market by disease area and discusses market data for leukemia, lymphoma and myeloma. This report involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. Regional overviews provide information on the epidemiology of blood cancer by country and region and detailed market data for each region.

Market dynamics, such as trends and challenges, are discussed in the report.Global market drivers, trends and challenges influencing the blood cancer therapeutic market are also captured in this report.

Detailed analyses of competitive environments, blockbuster drugs, pipelines, patents, the regulatory landscape and the reimbursement landscape are included in the report.The regulatory scenario is discussed for the United States, Europeand Japan to provide an overview of regulations for new drug launches.

The reimbursement scenario is outlined for the United States and Europe to provide an overview to readers.The pipeline analysis chapter discusses four major disease areas to provide details about major pipeline developments.

The competitive landscape discusses major manufacturers involved in the blood cancer therapeutic market, key developments and product offerings.

Report Includes:
- 41 data tables and 48 additional tables
- An overview of the global blood cancer therapeutics markets within the industry
- Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Regional dynamics of the market covering North America, Europe, Asia-Pacific and other emerging economies
- Discussion of major drivers, trends and challenges influencing blood cancer therapeutics market
- Information on the competitive environments, blockbuster drugs, pipeline analysis, patent analysis, and regulatory and reimbursement structure
- Coverage of regulatory environments for the United States, Europe and Japan; and information pertaining to the regulations for new drug launches
- A look at the reimbursement scenario outlined for the United States and Europe, and Pipeline analysis encompassing major disease area
- Examination of the competitive landscape and description of the major manufacturers involved in the blood cancer therapeutics market, key developments and product offerings
- Company profiles of leading market players, including AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc, F. Hofmann-La Roche Ltd., and Novartis AG

Summary
The blood cancer therapeutic market was valued at REDACTED in 2017 and is estimated to be REDACTED in 2018.The market is forecasted to reach REDACTED in 2023, growing at a CAGR of REDACTED during the forecast period (2018 to 2023).

The global leukemia therapeutic market was valued at REDACTED in 2017 and is forecasted to reach REDACTED in 2023.The market is witnessing several growth opportunities due to an increase in public and private initiatives to diagnosis the disease, a rise in the number of biopsies conducted annually and the availability of novel drugs.

These factors will propel market growth during the forecast years, and the market is projected to grow at a CAGR of REDACTED from2018 to 2023.

The global lymphoma therapeutic market is currently estimated to be worth REDACTED in 2018 and is forecasted to reach REDACTED in 2023.There are several drug approvals for lymphoma involving drug targets as antibody-drug conjugates, programmed death-1 receptor/programmed death ligands and microtubules, among others.

The market has several growth opportunities due to premium-priced drug therapies.There are several clinical trials being conducted to bring forth new therapies with novel drug targets.

It was reported that there were 217 active drugs under clinical trials for non-Hodgkin lymphoma in 2018. These factors will propel the growth of the market during the forecast years; it is projected to grow at a CAGR of REDACTED from 2018 to 2023.

The global multiple myeloma therapeutic market is currently estimated to be worth REDACTED in 2018 and is forecasted to reach REDACTED in 2023.The market is undergoing several advances, such as the approval of several drug therapies that have improved overall survival.

From 2011 to 2018, nearly seven drugs were approved, including Kyprolis, Imnovid, Pomalyst, Ninlaro, Farydak, Empliciti and Darzalex, which have increased the overall survival of multiple myeloma patients by nearly 23 months.There are several drugs in clinical trials that have the potential to be blockbusters.

The market is highly attractive, and ongoing research will propel the growth of the multiple myeloma market. It is forecasted to grow at a CAGR of REDACTED during the forecast years, 2018 to 2023.

Read the full report: https://www.reportlinker.com/p05691568 

Contact Clare: clare@reportlinker.com 
US: (339)-368-6001 
Intl: +1 339-368-6001